Posted in Regulatory FDA hands another rejection to Replimune’s melanoma therapy April 13, 2026 Pharmaphorum Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses. RegulatoryOncologyRead full story